Open Science in Brief, February 2022

      Getting it right: ENDS and HTPs: Challenges and pitfalls in aerosol analysis

      Nicotine, though addictive and not risk free, is not the primary cause of smoking related diseases. Therefore, the innovation of products that have a nicotine-containing aerosol, without tobacco combustion, can provide adult smokers with a better alternative if they intend to continue smoking. 

      With every new product that is developed, we need to accurately measure levels of harmful or potentially harmful chemicals. In addition, the characterization of the aerosol needs to be carried out to ensure that not only levels of these chemicals are reduced, compared to cigarette smoke, but also whether no new harmful compounds are formed. 

      This is why the methods that we at Philip Morris International (PMI), and others, use to analyze these chemicals are so important, and this is the topic that was addressed during Open Science in Brief February 2022. 

      Three of our leading scientists Moira Gilchrist, VP Strategic & Scientific Communications, Maurice Smith, Senior Scientific Advisor, and Catherine Goujon-Ginglinger, Head of Chemistry Research, discussed the analysis of both targeted and untargeted screening of toxicants in the aerosols of smoke-free products and other alternatives. They also discussed external publications that have touched on this issue.

      Read these publications for more details:

      Getting it right:

      ENDS and HTPs: Challenges and pitfalls in aerosol analysis

      Open Science in Brief event was held February 24, 2022. The 30-minute session was hosted on our Open Science platform, and was simultaneously broadcasted on PMIScience LinkedIn. The recording is available below and on LinkedIn